CymaBay Therapeutics (NASDAQ:CBAY) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY) in a report published on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the company. William Blair cut CymaBay Therapeutics from an outperform rating to a market perform rating in a research note on Monday, February 12th. Raymond James cut shares of CymaBay Therapeutics from an outperform rating to a market perform rating and set a $32.50 target price for the company. in a report on Tuesday, February 13th. B. Riley reaffirmed a neutral rating and issued a $32.50 target price (up from $29.00) on shares of CymaBay Therapeutics in a research report on Tuesday, February 13th. Cantor Fitzgerald lowered CymaBay Therapeutics from an overweight rating to a neutral rating and set a $32.50 price objective on the stock. in a report on Tuesday, February 13th. Finally, Lifesci Capital downgraded CymaBay Therapeutics from an outperform rating to a market perform rating in a report on Wednesday, February 14th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus price target of $28.65.

CymaBay Therapeutics Stock Performance

Shares of CBAY opened at $32.48 on Friday. The firm has a market capitalization of $3.73 billion, a price-to-earnings ratio of -33.48 and a beta of 0.32. The firm’s fifty day simple moving average is $32.41 and its 200-day simple moving average is $25.10. CymaBay Therapeutics has a twelve month low of $7.26 and a twelve month high of $32.50.

CymaBay Therapeutics (NASDAQ:CBAY) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). The business had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.42 million. On average, analysts predict that CymaBay Therapeutics will post -1.38 earnings per share for the current fiscal year.

Insider Activity at CymaBay Therapeutics

In other CymaBay Therapeutics news, Director Janet Dorling sold 6,000 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $31.97, for a total transaction of $191,820.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CymaBay Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CBAY. SG Americas Securities LLC acquired a new stake in shares of CymaBay Therapeutics in the 3rd quarter valued at approximately $230,000. Strategic Blueprint LLC raised its position in CymaBay Therapeutics by 6.3% in the third quarter. Strategic Blueprint LLC now owns 16,800 shares of the biopharmaceutical company’s stock worth $250,000 after acquiring an additional 1,000 shares in the last quarter. Raymond James & Associates lifted its holdings in CymaBay Therapeutics by 14.7% in the third quarter. Raymond James & Associates now owns 39,515 shares of the biopharmaceutical company’s stock valued at $589,000 after acquiring an additional 5,050 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in shares of CymaBay Therapeutics by 3.5% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 101,329 shares of the biopharmaceutical company’s stock worth $1,511,000 after purchasing an additional 3,434 shares in the last quarter. Finally, Emerald Advisers LLC acquired a new position in shares of CymaBay Therapeutics during the 3rd quarter worth $14,668,000. Hedge funds and other institutional investors own 95.03% of the company’s stock.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC).